{
    "clinical_study": {
        "@rank": "75689", 
        "arm_group": {
            "arm_group_label": "Menstrual blood stem cells", 
            "arm_group_type": "Experimental", 
            "description": "1x10*7 cells/kg, IV(in the vein) twice a week. Number of course for two weeks."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether human menstrual blood-derived stem cells\n      are effective in the treatment of infection of H7N9 virus caused acute lung injury."
        }, 
        "brief_title": "Using Human Menstrual Blood Cells to Treat Acute Lung Injury Caused by H7N9 Bird Flu Virus Infection", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Lung Injury", 
            "Acute Respiratory Distress Syndrome (ARDS)", 
            "Multiple Organ Failure"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Multiple Organ Failure", 
                "Respiratory Distress Syndrome, Newborn", 
                "Respiratory Distress Syndrome, Adult", 
                "Acute Lung Injury", 
                "Lung Injury", 
                "Wounds and Injuries"
            ]
        }, 
        "detailed_description": {
            "textblock": "1. recruiting volunteers of H7N9 infection: age > 18; patients signed with the informed\n           consent; APACHE II > 20 score\n\n        2. patients infused with menstrual blood progenitor cells infusion dose: 1~10\u00d710*7\n           cells/kg infusion frequency: 2 times a week, 2 weeks for infusion\n\n        3. test items and standard spirits lifted; pulmonary function improved; lung image injury\n           improved"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical diagnosis of H7N9 infection\n\n          -  must be critical injured for lung tissues\n\n        Exclusion Criteria:\n\n          -  cancer diseases\n\n          -  pregnancy\n\n          -  mental disorder\n\n          -  allergic constitution\n\n          -  severe inflammation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02095444", 
            "org_study_id": "SEB-2014-2-20"
        }, 
        "intervention": {
            "arm_group_label": "Menstrual blood stem cells", 
            "description": "10*7 cells/kg, intravenous injection for 4 times during two weeks", 
            "intervention_name": "Menstrual blood stem cells", 
            "intervention_type": "Drug", 
            "other_name": "Menstrual blood stem cells"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 20, 2014", 
        "location": {
            "contact": {
                "email": "cxiang@zju.edu.cn", 
                "last_name": "Charlie Xiang, Doctor", 
                "phone": "86-571-87236426"
            }, 
            "facility": {
                "address": {
                    "city": "Hangzhou", 
                    "country": "China", 
                    "state": "Zhejiang", 
                    "zip": "310003"
                }, 
                "name": "State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase1 Study of Recombinant Stem Cells That Repair Lung Injury in H7N9 Infected Patients", 
        "overall_contact": {
            "email": "cxiang@zju.edu.cn", 
            "last_name": "Charle Xiang, Doctor", 
            "phone": "86-571-87236426"
        }, 
        "overall_official": {
            "affiliation": "State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, School of Medicine, Zhejiang University", 
            "last_name": "Charlie Xiang, Doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The degree of lung injury", 
            "safety_issue": "Yes", 
            "time_frame": "14 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02095444"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "S-Evans Biosciences Co.,Ltd.", 
        "sponsors": {
            "collaborator": {
                "agency": "First Affiliated Hospital of Zhejiang University", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "S-Evans Biosciences Co.,Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}